Literature DB >> 25783671

A comprehensive assessment of environmental exposures among 1000 North American patients with primary sclerosing cholangitis, with and without inflammatory bowel disease.

J E Eaton1, B D Juran, E J Atkinson, E M Schlicht, X Xie, M de Andrade, C S Lammert, V A Luketic, J A Odin, A A Koteish, K V Kowdley, K B Chopra, G M Hirschfield, N P Chalasani, K N Lazaridis.   

Abstract

BACKGROUND: The relationships between primary sclerosing cholangitis (PSC) and the environment are largely unknown. AIM: To validate associations reported in previous studies and to identify novel environmental exposures among PSC patients.
METHODS: We performed a multicenter, case-control analysis utilising self-administered questionnaires. Responses between cases (n = 1000) and controls (n = 663) were compared using multivariable logistic regression adjusted for age and gender. The model was further stratified based on inflammatory bowel disease (IBD) status (with IBD n = 741 without IBD n = 259).
RESULTS: Smoking was associated with PSC only when IBD was present (OR, 0.5; 95% CI 0.4-0.7) but not among those PSC patients without IBD (OR, 0.9; 95% CI 0.7-1.2). Compared to controls, women with PSC (irrespective of the presence of IBD) were less likely to have received hormone replacement therapy (HRT; OR, 0.5; 95% CI 0.4-0.7) and were more likely to have recurrent urinary tract infections (OR, 1.6; 95% CI 1.2-2.3). PSC patients regardless of gender or IBD status were less likely to eat fish (OR, 0.4; 95% CI 0.3-0.6) and grilled/barbecued meat (OR, 0.8; 95% CI 0.7-0.9). In contrast, PSC patients with and without IBD were more likely to consume steak/burgers that were more well done (OR, 1.3; 95% CI 1.2-1.5).
CONCLUSIONS: IBD (rather than PSC) is associated with smoking. Women with PSC are more likely to have recurrent urinary tract infections and less likely to receive HRT. Dietary intake and methods of food preparation differ in PSC patients when compared to controls.
© 2015 John Wiley & Sons Ltd.

Entities:  

Mesh:

Year:  2015        PMID: 25783671      PMCID: PMC4402146          DOI: 10.1111/apt.13154

Source DB:  PubMed          Journal:  Aliment Pharmacol Ther        ISSN: 0269-2813            Impact factor:   8.171


  46 in total

1.  Beneficial effect of docosahexaenoic acid on cholestatic liver injury in rats.

Authors:  Wen-Ying Chen; Shih-Yi Lin; Hung-Chuan Pan; Su-Lan Liao; Yu-Han Chuang; Yu-Ju Yen; Szu-Yin Lin; Chun-Jung Chen
Journal:  J Nutr Biochem       Date:  2011-04-15       Impact factor: 6.048

Review 2.  Geographical variability and environmental risk factors in inflammatory bowel disease.

Authors:  Siew C Ng; Charles N Bernstein; Morten H Vatn; Peter Laszlo Lakatos; Edward V Loftus; Curt Tysk; Colm O'Morain; Bjorn Moum; Jean-Frédéric Colombel
Journal:  Gut       Date:  2013-01-18       Impact factor: 23.059

Review 3.  n-3 fatty acids, inflammation and immunity: new mechanisms to explain old actions.

Authors:  Philip C Calder
Journal:  Proc Nutr Soc       Date:  2013-05-14       Impact factor: 6.297

4.  Emigration to western industrialized countries: A risk factor for developing inflammatory bowel disease.

Authors:  M Barreiro-de Acosta; A Alvarez Castro; R Souto; M Iglesias; A Lorenzo; J E Dominguez-Muñoz
Journal:  J Crohns Colitis       Date:  2011-06-22       Impact factor: 9.071

5.  The safety and efficacy of oral docosahexaenoic acid supplementation for the treatment of primary sclerosing cholangitis - a pilot study.

Authors:  C R Martin; P G Blanco; J C Keach; J L Petz; M M Zaman; K R Bhaskar; J E Cluette-Brown; S Gautam; S Sheth; N H Afdhal; K D Lindor; S D Freedman
Journal:  Aliment Pharmacol Ther       Date:  2011-11-30       Impact factor: 8.171

Review 6.  Pathogenesis of primary sclerosing cholangitis and advances in diagnosis and management.

Authors:  John E Eaton; Jayant A Talwalkar; Konstantinos N Lazaridis; Gregory J Gores; Keith D Lindor
Journal:  Gastroenterology       Date:  2013-07-01       Impact factor: 22.682

7.  A comparative in vitro investigation into the effects of cooked meats on the human faecal microbiota.

Authors:  Qing Shen; Yin An Chen; Kieran M Tuohy
Journal:  Anaerobe       Date:  2010-10-08       Impact factor: 3.331

8.  Questionnaire based assessment of risk factors for primary biliary cirrhosis.

Authors:  Craig Lammert; Douglas L Nguyen; Brian D Juran; Erik Schlicht; Joseph J Larson; Elizabeth J Atkinson; Konstantinos N Lazaridis
Journal:  Dig Liver Dis       Date:  2013-03-11       Impact factor: 4.088

9.  Effect of dietary advanced glycation end products on mouse liver.

Authors:  Raza Patel; Susan S Baker; Wensheng Liu; Sonal Desai; Razan Alkhouri; Rafal Kozielski; Lucy Mastrandrea; Adil Sarfraz; Weijing Cai; Helen Vlassara; Mulchand S Patel; Robert D Baker; Lixin Zhu
Journal:  PLoS One       Date:  2012-04-04       Impact factor: 3.240

Review 10.  The role of E. coli infection in the pathogenesis of primary biliary cirrhosis.

Authors:  Dimitrios P Bogdanos; Harold Baum; Diego Vergani; Andrew K Burroughs
Journal:  Dis Markers       Date:  2010       Impact factor: 3.434

View more
  15 in total

Review 1.  Studying the Exposome to Understand the Environmental Determinants of Complex Liver Diseases.

Authors:  Angela C Cheung; Douglas I Walker; Brian D Juran; Gary W Miller; Konstantinos N Lazaridis
Journal:  Hepatology       Date:  2019-12-24       Impact factor: 17.425

2.  The features of mucosa-associated microbiota in primary sclerosing cholangitis.

Authors:  J Torres; X Bao; A Goel; J-F Colombel; J Pekow; B Jabri; K M Williams; A Castillo; J A Odin; K Meckel; F Fasihuddin; I Peter; S Itzkowitz; J Hu
Journal:  Aliment Pharmacol Ther       Date:  2016-02-09       Impact factor: 8.171

3.  Differences in Phenotypes and Liver Transplantation Outcomes by Age Group in Patients with Primary Sclerosing Cholangitis.

Authors:  Jacqueline B Henson; Yuval A Patel; Julius M Wilder; Jiayin Zheng; Shein-Chung Chow; Lindsay Y King; Andrew J Muir
Journal:  Dig Dis Sci       Date:  2017-04-08       Impact factor: 3.199

4.  Epigenetics in the Primary Biliary Cholangitis and Primary Sclerosing Cholangitis.

Authors:  Angela C Cheung; Nicholas F LaRusso; Gregory J Gores; Konstantinos N Lazaridis
Journal:  Semin Liver Dis       Date:  2017-05-31       Impact factor: 6.115

Review 5.  Primary Sclerosing Cholangitis: Multiple Phenotypes, Multiple Approaches.

Authors:  Souvik Sarkar; Christopher L Bowlus
Journal:  Clin Liver Dis       Date:  2015-10-06       Impact factor: 6.126

Review 6.  Primary Sclerosing Cholangitis.

Authors:  Konstantinos N Lazaridis; Nicholas F LaRusso
Journal:  N Engl J Med       Date:  2016-09-22       Impact factor: 91.245

7.  Primary Sclerosing Cholangitis Is Not Rare Among Blacks in a Multicenter North American Consortium.

Authors:  David S Goldberg; Cynthia Levy; Kidist Yimam; Stuart C Gordon; Lisa Forman; Elizabeth Verna; Lei Yu; Robert Rahimi; Kathleen Schwarz; Bertus Eksteen; Daniel Pratt; James L Boyer; David Assis; Christopher Bowlus
Journal:  Clin Gastroenterol Hepatol       Date:  2017-11-02       Impact factor: 11.382

8.  The gut microbiota, bile acids and their correlation in primary sclerosing cholangitis associated with inflammatory bowel disease.

Authors:  J Torres; C Palmela; H Brito; X Bao; H Ruiqi; P Moura-Santos; J Pereira da Silva; A Oliveira; C Vieira; K Perez; S H Itzkowitz; J F Colombel; L Humbert; D Rainteau; M Cravo; C M Rodrigues; J Hu
Journal:  United European Gastroenterol J       Date:  2017-05-05       Impact factor: 4.623

9.  Association between smoking and risk of primary sclerosing cholangitis: A systematic review and meta-analysis.

Authors:  Karn Wijarnpreecha; Panadeekarn Panjawatanan; Omar Y Mousa; Wisit Cheungpasitporn; Surakit Pungpapong; Patompong Ungprasert
Journal:  United European Gastroenterol J       Date:  2018-02-21       Impact factor: 4.623

Review 10.  Patient-reported outcome measures used in patients with primary sclerosing cholangitis: a systematic review.

Authors:  Fatima Isa; Grace M Turner; Geetinder Kaur; Derek Kyte; Anita Slade; Tanya Pankhurst; Larissa Kerecuk; Thomas Keeley; James Ferguson; Melanie Calvert
Journal:  Health Qual Life Outcomes       Date:  2018-07-05       Impact factor: 3.186

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.